1. A potent, broadly neutralizing human monoclonal antibody that efficiently protects hACE2-transgenic mice from infection with the Wuhan, BA.5, and XBB.1.5 SARS-CoV-2 variants.
- Author
-
Guselnikov, Sergey V., Baranov, Konstantin O., Kulemzin, Sergey V., Belovezhets, Tatyana N., Chikaev, Anton N., Murasheva, Svetlana V., Volkova, Olga Y., Mechetina, Ludmila V., Najakshin, Alexander M., Chikaev, Nikolai A., Solodkov, Pavel P., Sergeeva, Maria V., Smirnov, Alexander V., Serova, Irina A., Serov, Oleg L., Markhaev, Alexander G., Kononova, Yulia V., Alekseev, Alexander Y., Gulyaeva, Marina A., and Danilenko, Daria M.
- Subjects
SARS-CoV-2 Omicron variant ,SARS-CoV-2 ,SARS virus ,BREAKTHROUGH infections ,VIRAL variation - Abstract
The COVID-19 pandemic has uncovered the high genetic variability of the SARSCoV-2 virus and its ability to evade the immune responses that were induced by earlier viral variants. Only a few monoclonal antibodies that have been reported to date are capable of neutralizing a broad spectrum of SARS-CoV-2 variants. Here, we report the isolation of a new broadly neutralizing human monoclonal antibody, iC1. The antibody was identified through sorting the SARS-CoV-1 RBD-stained individual B cells that were isolated from the blood of a vaccinated donor following a breakthrough infection. In vitro, iC1 potently neutralizes pseudoviruses expressing a wide range of SARS-CoV-2 Spike variants, including those of the XBB sublineage. In an hACE2-transgenic mouse model, iC1 provided effective protection against the Wuhan strain of the virus as well as the BA.5 and XBB.1.5 variants. Therefore, iC1 can be considered as a potential component of the broadly neutralizing antibody cocktails resisting the SARS-CoV-2 mutation escape. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF